BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15853584)

  • 1. Delivery systems and molecular targets of mechanism-based therapies for GBM.
    Phuphanich S; Brat DJ; Olson JJ
    Expert Rev Neurother; 2004 Jul; 4(4):649-63. PubMed ID: 15853584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of nanoparticles for drug delivery in glioblastoma multiforme.
    Jain KK
    Expert Rev Neurother; 2007 Apr; 7(4):363-72. PubMed ID: 17425491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
    Reardon DA; Wen PY
    Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts.
    Gadji M; Crous AM; Fortin D; Krcek J; Torchia M; Mai S; Drouin R; Klonisch T
    Eur J Pharmacol; 2009 Dec; 625(1-3):23-30. PubMed ID: 19836372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autocrine platelet-derived growth factor-dependent gene expression in glioblastoma cells is mediated largely by activation of the transcription factor sterol regulatory element binding protein and is associated with altered genotype and patient survival in human brain tumors.
    Ma D; Nutt CL; Shanehsaz P; Peng X; Louis DN; Kaetzel DM
    Cancer Res; 2005 Jul; 65(13):5523-34. PubMed ID: 15994924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatment strategies for malignant gliomas.
    Sathornsumetee S; Rich JN
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):1087-104. PubMed ID: 16831080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The EGFRvIII variant in glioblastoma multiforme.
    Gan HK; Kaye AH; Luwor RB
    J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
    Razis E; Selviaridis P; Labropoulos S; Norris JL; Zhu MJ; Song DD; Kalebic T; Torrens M; Kalogera-Fountzila A; Karkavelas G; Karanastasi S; Fletcher JA; Fountzilas G
    Clin Cancer Res; 2009 Oct; 15(19):6258-66. PubMed ID: 19789313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort.
    Pollack IF; Hamilton RL; James CD; Finkelstein SD; Burnham J; Yates AJ; Holmes EJ; Zhou T; Finlay JL;
    J Neurosurg; 2006 Nov; 105(5 Suppl):418-24. PubMed ID: 17328268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
    Argyriou AA; Giannopoulou E; Kalofonos HP
    Oncology; 2009; 77(1):1-11. PubMed ID: 19439998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Convection-enhanced delivery to achieve widespread distribution of viral vectors: Predicting clinical implementation.
    Debinski W; Tatter SB
    Curr Opin Mol Ther; 2010 Dec; 12(6):647-53. PubMed ID: 21154156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
    Simpson L; Galanis E
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas.
    Rand V; Huang J; Stockwell T; Ferriera S; Buzko O; Levy S; Busam D; Li K; Edwards JB; Eberhart C; Murphy KM; Tsiamouri A; Beeson K; Simpson AJ; Venter JC; Riggins GJ; Strausberg RL
    Proc Natl Acad Sci U S A; 2005 Oct; 102(40):14344-9. PubMed ID: 16186508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray.
    Yin D; Ogawa S; Kawamata N; Tunici P; Finocchiaro G; Eoli M; Ruckert C; Huynh T; Liu G; Kato M; Sanada M; Jauch A; Dugas M; Black KL; Koeffler HP
    Mol Cancer Res; 2009 May; 7(5):665-77. PubMed ID: 19435819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug cocktails for effective treatment of glioblastoma multiforme.
    Debinski W
    Expert Rev Neurother; 2008 Apr; 8(4):515-7. PubMed ID: 18416653
    [No Abstract]   [Full Text] [Related]  

  • 16. Epigenetic mechanisms in glioblastoma multiforme.
    Nagarajan RP; Costello JF
    Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The infrequent simultaneous genetic alterations in glioblastoma multiforme (LOH 10, 17, 19q, TP53 mutation and EGFR amplification) with short clinical course.
    Jesionek-Kupnicka D; Kulczycka D; Rieske P; Szybka M; Jabłońska J; Potemski P; Kolasa P; Liberski PP; Kordek R
    Pol J Pathol; 2007; 58(2):79-85. PubMed ID: 17715673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting malignant glioma survival signalling to improve clinical outcomes.
    Wong ML; Kaye AH; Hovens CM
    J Clin Neurosci; 2007 Apr; 14(4):301-8. PubMed ID: 17276069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic analyses for predictors of radiation response in glioblastoma.
    Shih HA; Betensky RA; Dorfman MV; Louis DN; Loeffler JS; Batchelor TT
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):704-10. PubMed ID: 15978739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme.
    Jagannathan J; Prevedello DM; Dumont AS; Laws ER
    Neurosurg Focus; 2006 Apr; 20(4):E8. PubMed ID: 16709039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.